< 1 minute read
Sep. 18, 2021

NLG802: An Oral Prodrug of IDO1 Inhibitor

NLG802

oral prodrug of IDO1 inhibitor completed Ph. I in solid tumors from derivatization of indoximod Eur. J. Med. Chem., May 1, 2020 NewLink Genetics, Ames, IA

twitterlinkedinprintemail